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ABSTRACT
Phosphodiesterase 4D7 was recently shown to be specifically over-expressed in 
localized prostate cancer, raising the question as to which regulatory mechanisms 
are involved and whether other isoforms of this gene family (PDE4D) are affected 
under the same conditions.
We investigated PDE4D isoform composition in prostatic tissues using a total of 
seven independent expression datasets and also included data on DNA methylation, 
copy number and AR and ERG binding in PDE4D promoters to gain insight into their 
effect on PDE4D transcription.
We show that expression of PDE4D isoforms is consistently altered in primary 
human prostate cancer compared to benign tissue, with PDE4D7 being up-regulated 
while PDE4D5 and PDE4D9 are down-regulated. Disease progression is marked by an 
overall down-regulation of long PDE4D isoforms, while short isoforms (PDE4D1/2) 
appear to be relatively unaffected. While these alterations seem to be independent 
of copy number alterations in the PDE4D locus and driven by AR and ERG binding, 
we also observed increased DNA methylation in the promoter region of PDE4D5, 
indicating a long lasting alteration of the isoform composition in prostate cancer 
tissues.
We propose two independent metrics that may serve as diagnostic and prognostic 
markers for prostate disease: (PDE4D7 - PDE4D5) provides an effective means for 
distinguishing PCa from normal adjacent prostate, whereas PDE4D1/2 - (PDE4D5 + 
PDE4D7 + PDE4D9) offers strong prognostic potential to detect aggressive forms of 
PCa and is associated with metastasis free survival. Overall, our findings highlight the 
relevance of PDE4D as prostate cancer biomarker and potential drug target.
INTRODUCTION
With an estimated 417,000 new cases in 2014 in 
Europe, prostate cancer (PCa) remains the most often 
diagnosed gender-specific carcinoma for men [1]. The 
current routine of diagnosing PCa results in a significant 
number of unnecessary biopsies and treatments of non-
cancerous, benign prostate conditions and non-aggressive 
cancers, leading to severe negative effects for both men 
and healthcare systems [2, 3].
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Next to well-studied pathways such as androgen 
receptor (AR) and PI3K/AKT, cyclic AMP (cAMP) 
has been shown to play a role in the development and 
progression of PCa [4]. The metabolism of cAMP in 
cells is complex and tailored by spatial and signalling 
cross-talk considerations involving both a large family 
of adenylyl cyclases responsible for its synthesis, and 
a large family of cyclic nucleotide phosphodiesterases 
(PDEs) responsible for its degradation [5]. It is now 
well recognized that when particular cAMP degrading 
PDEs are recruited to specific signalling complexes 
they create and control cAMP gradients around them, 
allowing spatially compartmentalised and time-dependent 
regulation of localized cAMP signalling [6, 7]. Protein 
domains involved in subcellular localization as well as 
independent regulatory mechanisms play a pivotal role in 
these processes, granting PDE isoforms the ability to fulfil 
functionally independent and unique roles in the cell [6, 8]. 
Thus, changes in the expression of distinct PDE isoforms 
can be expected to reprogram downstream signalling 
pathways during disease development and progression, 
providing potential targets for novel markers and 
therapeutic interventions [6]. Indeed, cAMP-degrading 
PDEs have been associated with several diseases in recent 
years, including stroke, acrodysostosis and COPD [9–
14], and more recently, expression of a specific PDE4D 
isoform (PDE4D7) has been related to prostate cancer [15, 
16].
The PDE4D7 transcript comprises the open reading 
frame for a long PDE4D isoform that contains both the 
UCR1 and UCR2 regulatory domains [17]. These protein 
domains are common to all long PDE4D isoforms with 
UCR1 being phosphorylated by PKA (cAMP dependent 
protein kinase A), when cAMP levels within the cell are 
elevated, leading to enzyme activation [18, 19]. Indeed, 
activation of long PDE4 isoforms, such as PDE4D7, 
by PKA provides a fundamental part of the cellular 
desensitization process to cAMP [6]. Long PDE4 isoforms 
can also be dynamically regulated through phosphorylation 
by other key signalling system kinases, namely, by ERK 
[20], MK2 [21], Cdk5 [22] and AMPK [23]. Additionally, 
PDE4D7 has been shown [15] to be specifically targeted to 
the sub-plasma membrane compartment in prostate cancer 
cells where it regulates local cAMP levels that are linked 
to cell proliferation [15].
We have previously shown that PDE4D7 is 
specifically overexpressed in both androgen sensitive 
PCa cells and in samples from patients with early 
androgen sensitive prostate disease [15, 16]. However, in 
marked contrast to this, once PCa cells become androgen 
insensitive/independent (castration resistant), expression 
of PDE4D7 declines [15, 16].
Here, we show that PDE4D isoform composition is 
altered in localized prostate cancer and that it can be used 
both as a diagnostic as well as a prognostic biomarker. In 
conjunction with our previous studies, we see that the long 
transcript isoform PDE4D7 is up-regulated in localized 
disease compared to normal adjacent prostate (NAP), 
while its expression diminishes with tumour progression. 
In contrast to PDE4D7, two other long isoforms, PDE4D5 
and PDE4D9, do not undergo an initial up-regulation in 
primary PCa and instead are increasingly down-regulated 
during disease progression. Moreover, we suggest that this 
change in isoform composition may be influenced by the 
DNA methylation of specific regulatory elements of the 
PDE4D locus. These findings highlight the potential of 
using condition-specific mRNA isoforms of the PDE4D 
gene as biomarkers and potential novel therapy targets to 
restore benign conditions.
RESULTS
The long isoforms PDE4D5 and PDE4D9 are 
significantly down-regulated in primary prostate 
cancer, independent of copy number alterations 
in the PDE4D gene locus
After previously identifying PDE4D7 as a novel 
biomarker candidate [16], we wanted to investigate the 
behaviour of other PDE4D transcript isoforms in PCa 
development and progression. Therefore, we focused 
on the nine major human PDE4D isoforms described in 
RefSeq and conducted a meta-analysis of six publicly 
available patient cohorts. Our analysis revealed that 
many PDE4D isoforms are seemingly expressed at stable 
levels when using Exon Arrays, whereas only PDE4D1/2, 
PDE4D5, PDE4D7, and PDE4D9 were detectable at 
higher levels in our independent qRT-PCR cohort of 
prostate tissues (see Figure 1 and Supplementary Figures 
S1-S5). These findings were supported by the TCGA 
PRAD RNA-seq cohort, which mostly agreed with 
RT-PCR results, despite few outlier samples showing 
expression of other isoforms (Supplementary Figure 
S6). Based on these findings, we focused on the above 
mentioned PDE4D isoforms, as they showed consistent 
expression profiles in all used cohorts. Using these criteria, 
we found that both PDE4D5 and PDE4D9 are significantly 
down-regulated in primary localized PCa when compared 
to benign samples. Moreover, patient samples derived 
from castration-resistant prostate cancer (CRPC) showed 
further down-regulation of both isoforms, in line with 
our previous findings for PDE4D7 [16]. Likewise, PCa 
metastasis samples followed this trend, but often displayed 
higher variance in PDE4D isoform expression, as can 
be expected given their very heterogeneous genomic 
background [24].
Since, partial or complete deletions of one or both 
alleles of the PDE4D gene have been reported previously 
in prostate cancer [25–27] we utilized TCGA SNP array 
data of matching patient samples to assess the potential 
impact of deletions occurring in PDE4D on isoform 
expression. Although we did observe a significant 
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reduction in gene expression upon loss of genetic material, 
both isoforms were also expressed at significantly lower 
levels in PCa samples which did not harbour a deletion 
when comparing to matching normal samples (Figure 2).
Androgen receptor and ERG are implicated in 
transcriptional regulation of PDE4D
Our previous work suggested an association 
between PDE4D7 expression and the presence of the 
TMPRSS2-ERG fusion gene [16]. We therefore set out 
to investigate whether there was any comparable ERG 
involvement in the expression of PDE4D5, PDE4D7 
and PDE4D9 in prostate disease. In order to do this, we 
assigned localized PCa samples to one of two groups 
based on an unsupervised clustering of ERG expression 
values by Partitioning Around Medoids and used available 
ERG IHC information of the EMC cohort to confirm 
the validity of this approach. Clustering based grouping 
showed good concordance with IHC results, assigning 
four additional samples (10.2%) to the ERG positive 
group (Supplementary Figure S7).
Interestingly, while we were able to confirm 
PDE4D7 overexpression in ERG positive PCa samples, 
PDE4D1/2 and PDE4D9 seemed unaffected by ERG, 
whereas PDE4D5 expression was altered significantly in 
Figure 1: Overview of PDE4D isoform expression in prostatic tissues. Normalized PDE4D isoform expression in the EMC 
dataset across different prostate conditions. CR – clinical recurrence, BCR – biochemical recurrence, CPRC – castration resistant prostate 
cancer. Significant differences (p < 0.05, Wilcoxon-Mann-Whitney test) are indicated with *.
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two out of five datasets, suggesting that any connection 
between PDE4D5 and ERG is weak at best (see 
Figure 3). Of note, the Erho dataset consistently showed 
significant changes for all isoforms, however, these likely 
do not reflect real events, as absolute log2 fold changes 
were small (|log2FC| < 1) except for PDE4D7 (data not 
shown). Therefore, ERG linkage discriminates between 
PDE4D7 and the grouping of PDE4D1/2, PDE4D5 and 
PDE4D9, where we see differences between these two 
groups in the change of their expression in prostate 
disease.
To investigate androgen-dependence of PDE4D 
isoform expression, we incorporated a public dataset of 
LNCaP cells measured after being kept either in androgen 
stripped medium (using dextran-coated charcoal - DCC) 
or after addition of the synthetic androgen R1881 [28]. 
While PDE4D9 expression was not altered after treatment, 
both PDE4D5 and PDE4D7 showed significant differences 
in expression after R1881 addition (Figure 4). Specifically, 
PDE4D5 expression appeared to be inhibited upon AR 
stimulation, while PDE4D7 was up-regulated in DCC by 
the synthetic androgen R1881 in LNCaP cells.
Figure 2: Relation of copy number events and PDE4D expression in the TCGA cohort. 32 normal adjacent prostate samples 
are compared to PCa samples with (n=12) and without (n=171) loss of genetic material in the PDE4D locus to investigate whether decreased 
expression occurs independently of PDE4D deletions. Significant differences in expression are denoted with * (p < 0.05, Wilcoxon-Mann-
Whitney test).
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Next, we made use of public ChIP-seq data from 
the VCaP PCa cell line [29] treated with R1881 in 
order to gather further evidence of AR involvement in 
PDE4D expression. In ChIP-seq, DNA binding proteins 
and associated chromatin are cross-linked, followed 
by immunoprecipitation of a protein of interest and 
subsequent sequencing of the associated DNA fragments, 
allowing a genome-wide localisation of its DNA binding 
sites. Overall, we found 31 ChIP-seq peaks for AR in 
PDE4D, two of which were near the first exon of PDE4D7 
(~2 kb and 3 kb upstream), while another was partially 
overlapping the first exon of PDE4D5 (see Supplementary 
Table S1). No peaks could be found in proximity to the 
PDE4D9 transcription start site (TSS), as the closest 
upstream and downstream peaks were found at an 
approximate distance of 85.5 kb and 44.2 kb, respectively. 
Since VCaP harbours the TMPRSS2-ERG gene fusion 
and ChIP-seq data for ERG was available from the same 
source, we included it in our analysis and found 43 ERG 
peaks in the PDE4D gene locus, of which some were 
found to partially overlap the first exon of each of the long 
isoforms PDE4D5, PDE4D7 and PDE4D9 (see Figure 5 
Figure 3: Investigating potential ERG regulation of PDE4D isoforms. Since only PDE4D7 has been previously reported as up-
regulated in ERG positive PCa samples [16], expression of PDE4D1/2, PDE4D5, PDE4D7 and PDE4D9 was tested in ERG negative and 
ERG positive samples across five Exon Array datasets (* = p < 0.05, ** = p < 0.001, Wilcoxon-Mann-Whitney test).
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and Supplementary Table S2). Since the number of ChIP-
seq peaks located in PDE4D appears to be rather high, 
we were wondering whether binding of AR and/or ERG 
within the gene locus occurs more often as compared to 
other regions. For this reason, we counted the number of 
AR and ERG peaks in 21,209 RefSeq gene loci and used 
these counts to construct empirical cumulative distribution 
functions (ECDFs) for both transcription factors. These 
ECDFs model the background distribution of the counts 
for both AR and ERG across all genes and enable us to 
calculate in which percentile the peak counts for AR and 
ERG in PDE4D are falling. Surprisingly, both AR and 
ERG were among the top 99.9% of all genes (99.953th 
and 99.995th percentiles, respectively), suggesting a 
very strong enrichment in AR and ERG binding within 
the PDE4D gene locus (see Supplementary Figure S8a). 
However, since PDE4D is a comparably large gene 
and spans approximately 1.5 Mb of genomic space, we 
repeated this analysis using more than three million 
randomly sampled genomic regions of 1.5 Mb size across 
all major chromosomes. Again, we found that PDE4D was 
highly enriched in AR and ERG binding peaks (95.151th 
and 87.624th percentiles, respectively) compared to random 
genomic stretches of comparable size (Supplementary 
Figure 4: Investigation of androgen receptor involvement in PDE4D expression. Expression of PDE4D isoforms in LNCaP 
cells with or without addition of the synthetic androgen R1881 [28].
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Figure S8b). As a whole, these data support the observed 
expression profiles and suggest an involvement of both AR 
and ERG in overall PDE4D isoform regulation.
DNA methylation of defined regions in PDE4D is 
altered in prostate cancer
To further study transcriptional regulation of 
the PDE4D locus, we obtained public data of DNA 
methylation in PCa patients from Gene Expression 
Omnibus (GEO) and TCGA and performed statistical 
analyses to identify hyper- and hypo-methylated regions 
in PCa as compared to normal adjacent prostate (NAP). 
The results of three different platforms determining 
DNA methylation patterns consistently detected hyper-
methylated regions, indicating active silencing of several 
PDE4D promoters in PCa, involving the transcription start 
site (TSS) of a total of five PDE4D isoforms, namely the 
short PDE4D1/2 isoforms and the long PDE4D4, PDE4D5 
and PDE4D8 isoforms (see Supplementary Figure S9).
To estimate the impact of these differentially 
methylated regions (DMRs) on isoform expression, we 
used Affymetrix Human Exon Array samples obtained 
from the same patients as the MeDIP-seq cohort [30, 31] 
and calculated Spearman’s correlation coefficient for each 
of the differentially methylated regions (DMRs) and the 
associated PDE4D isoform. Of the five TSS involved, 
PDE4D5 showed the strongest negative association (r = 
-0.571, Supplementary Table S3), while the four DMRs 
near the PDE4D4 TSS showed varying agreement 
between methylation and expression measurements, 
ranging from r = -0.215 to r = -0.394. These results follow 
the expected behaviour, as increased DNA methylation 
impedes transcription [32]. Since the PDE4D1 and 
PDE4D2 expression could not be independently measured 
with the Exon Arrays, a negative correlation (r = -0.517) 
was found for both. Lastly, PDE4D8 expression did not 
show any association with DNA methylation (r = -0.233), 
agreeing with our observation that this isoform is 
not consistently expressed in prostate tissues (see 
Supplementary Figure S1).
PDE4D isoforms can be used as diagnostic 
and prognostic signature for prostate cancer: 
application to prostate biopsies
Since PDE4D7 and PDE4D5 show opposing 
behaviours in prostatic tissues, we created a diagnostic 
signature based on the expression of PDE4D7 relative 
to that of PDE4D5 expression (PDE4D7 - PDE4D5). In 
order to evaluate its performance in distinguishing PCa 
and non-PCa samples, we carried out ROC analyses in 
Figure 5: AR and ERG binding peaks in PDE4D in the VCaP cell line. To visualize AR and ERG binding in PDE4D, genomic 
locations of ChIP-seq peaks (GSE14092) denoting AR binding sites are coloured blue, while ERG peaks are coloured in red. If peaks of 
both transcription factors overlap, the affected genomic regions are coloured in black. A genomic region surrounding each transcription start 
site (TSS) is used to highlight binding events that could influence transcription.
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all compatible datasets and compared the resulting AUCs 
with PCA3 (Supplementary Table S4). Overall, our 
diagnostic signature performed on par with PCA3, with 
AUCs ranging from 0.839 to 0.934 compared to 0.857 to 
0.921.
In order to evaluate the value of PDE4D as a 
clinical biomarker, we used surgical resection materials 
of eighteen patients and subjected them to needle biopsies 
to obtain material from distinct areas, simulating both true 
positive and false negative biopsies (see Supplementary 
Table S5). In total, four biopsies with gradually increasing 
distance from the tumour were taken per patient (within 
tumour, edge of tumour, 5 mm from edge, and 10 mm 
from edge) and PDE4D5 as well as PDE4D7 expression 
were measured by qPCR. Ct values of both isoforms were 
normalized to several reference genes (see Methods) and 
adjusted to baseline expression in NAP tissue (10 mm 
from edge). Both expression profiles showed inverse 
correlation, with PDE4D5 expression decreasing in the 
vicinity of the tumour, while PDE4D7 expression as 
well as the diagnostic signature gradually increasing (see 
Figure 6), confirming our earlier findings. Additionally, 
a transient change of PDE4D isoform expression at the 
tumour edge might suggest that nearby adjacent normal 
tissue is influenced by tumour presence through a ‘field 
effect’, but could also be due to averaging signals from 
normal and cancerous cells.
Notably, expression of all long PDE4D isoforms 
including PDE4D5 and PDE4D7 appears to decrease 
during PCa progression (see Figure 1 and Supplementary 
Figures S2-S3), while expression of the super-short 
PDE4D isoforms PDE4D1 and PDE4D2 seemed to be 
affected to a lesser extent. On this basis, we decided to 
create a prognostic signature based on the expression level 
of PDE4D1/2 relative to the sum of the expression levels 
of the long PDE4D5, PDE4D7 and PDE4D9 isoforms 
PDE4D7. The performance of this signature was then 
evaluated in the Exon Array cohorts. Since, three datasets 
had appropriate follow-up available, we used clinical 
recurrence (CR) defined as development of metastases 
after RP as clinical endpoint. Overall, our signature 
performed well in distinguishing patients with CR from 
those without, yielding AUCs of 0.826, 0.794 and 0.614 
for the EMC, Taylor and Erho cohort, respectively 
(Supplementary Table S4). Since the EMC dataset offered 
time to biochemical recurrence (BCR), metastases-free 
as well as overall survival time as follow-up information, 
we performed a Kaplan-Meier analysis for this dataset 
using our prognostic PDE4D signature. Two categories 
(signature high and low) were defined by Partitioning 
Around Medoids (PAM) and left-censoring was applied, 
resulting in well separated curves for both metastases-free 
and overall survival (p < 0.05, see Figure 7). Subsequently, 
we used Cox proportional hazards regression model to 
Figure 6: Applying the diagnostic PDE4D signature in needle biopsies. Expression of PDE4D5 and PDE4D7 in relation to 
distance to the tumour as measured by qRT-PCR in prostate tumour biopsies (n = 18). Error bars represent standard error of the mean.
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evaluate whether our PDE4D signature is an independent 
predictor for clinical metastasis, BCR and overall 
survival, taking into account the pre-operational PSA, 
Gleason score, pathological stage, surgical margins and 
patient age. For both metastases-free as well as overall 
survival, the prognostic PDE4D signature was found to 
be an independent predictor (p < 0.1), though confidence 
intervals were large due to low numbers of samples and 
events (Supplementary Table S6).
DISCUSSION
Our investigation of the transcriptional dynamics of 
the PDE4D gene locus revealed a previously undescribed 
promoter switch involving the major contributors of 
PDE4D activity in normal prostate, namely the PDE4D5 
and PDE4D9 long forms, as well as the prostate cancer-
associated long isoform PDE4D7 [15, 16]. Unique 
promoters for each PDE4D isoform, located upstream 
Figure 7: Survival analysis for prognostic PDE4D signature. Using the prognostic PDE4D signature to distinguish between 
outcomes, Kaplan Meier curves for three clinical endpoints were created based on the EMC dataset. Assignment of samples to the high and 
low signature group was performed by clustering of samples according to their signature values using Partitioning Around Medoids (PAM).
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of the exon(s) encoding their unique N-terminal regions 
allow for the independent regulation of the different 
mRNA and corresponding protein expression [6, 9, 
33]. Here in this study we provide the first evidence of 
condition-specific PDE4D promoter switching in a cancer 
context.
Isoform switching in various genes (such as PKM, 
CXCR3 and FGR2 [34–36]) during cancer development 
has been described in several cancer types including 
prostate cancer [37–40], and likewise tumour-specific 
isoforms of known genes have been identified previously 
[41]. Indeed, the androgen receptor variant 7 (AR-V7) 
provides a particularly important example of a PCa-
specific isoform that is constitutively active and ligand-
independent, contributing to castration resistance of 
prostate cancer cells [42, 43]. Furthermore, alternative 
promoter usage of the androgen-regulated gene TMPRSS2 
as part of the TMPRSS2-ERG fusion gene also has been 
associated with clinical outcome [44, 45].
Interestingly, mounting evidence suggests 
crosstalk between AR and cAMP signalling pathways, 
with important cAMP downstream targets such as PKA 
and ERK interacting either with the AR or AR target 
genes [4, 46–48]. PDEs, in providing the sole route for 
degrading cAMP are poised to play a key regulatory role, 
particularly so as the targeting of particular isoforms to 
distinct signalling complexes confers a spatial aspect that 
allows particular isoforms to have specific functional roles 
[6]. Therefore, it is particularly intriguing to find that 
specific PDE4D isoforms expressed in prostatic tissues 
appear to be androgen regulated (PDE4D7 and PDE4D5), 
suggesting a complex network of interactions that links 
both pathways. We should, however, mention that studies 
of PDE4D7 expression in the VCaP prostate cancer cell 
line implied that it was not directly regulated by AR [15]. 
However, VCaP harbours genomic rearrangements on 
chr5q that are characteristic of chromothripsis, and more 
importantly, PDE4D is reportedly involved in gene fusions 
with FAM172A and C5orf47 [49]. With regards to the AR-
induced up-regulation of PDE4D7 observed in LNCaP 
cells, these structural rearrangements in VCaP could be 
involved in a loss of AR-mediated regulation of PDE4D7 
due to relocation or deletion of regulatory elements such as 
AR binding elements. An alternative explanation could be 
that PDE4D7 expression is indirectly linked to AR activity, 
as its promoter region overlaps PART1, a known AR 
target gene that showed clear association with androgen 
treatment in VCaP [15, 50, 51]. In the Exon Array datasets 
that we analysed, both genes seem to be co-expressed 
in prostatic tissues (mean Spearman’s rho = 0.7269). 
However, given the fact that PDE4D5 was significantly 
down-regulated in LNCaP upon AR stimulation as well, 
we believe that AR directly influences PDE4D isoform 
expression through interaction with proximal or distal 
regulatory elements [52, 53]. This hypothesis is supported 
by the ChIP-seq data for AR, which identifies numerous 
binding peaks for AR in the PDE4D gene locus, including 
the PDE4D5 and PDE4D7/PART1 promoter regions.
Similarly, ERG seems to have a major contribution 
on PDE4D isoform expression, with us previously 
reporting that PDE4D7 is up-regulated in TMPRSS2-
ERG positive PCa [16]. Here, we provided further 
ChIP-seq support for ERG involvement in PDE4D 
expression. However, the Exon Array datasets analysed 
here do not provide conclusive evidence for a link of ERG 
overexpression with other isoforms, such as PDE4D5. It 
appears therefore plausible that ERG overexpression may 
be specifically linked to PDE4D7 expression, highlighting 
a connection of the latter to the AR pathway, as well as its 
potential oncogenic role [15].
To investigate whether DNA methylation could be 
involved in the promoter switch uncovered in this study, 
we analysed three independent datasets based on different 
technologies, whereupon we discovered consistent increases 
of DNA methylation near the PDE4D5 TSS in PCa samples. 
In conjunction with the observed AR-mediated down-
regulation of PDE4D5, these results could well explain 
the profound down-regulation of PDE4D5 in localized and 
advanced PCa and could hint at a protective function in 
normal prostate that is inhibited by gene silencing in PCa. 
In addition, we found increased DNA methylation near the 
PDE4D1/2 TSS that could not be linked to significantly 
altered gene expression, while other isoforms showing 
differential methylation (PDE4D4, PDE4D8) do not seem 
to be consistently expressed in prostatic tissues. Indeed, it 
is even possible that the increased DNA methylation in the 
promoter regions of specific PDE4D isoforms might induce 
promoter switching to PDE4D7 by inhibiting expression of 
other PDE4D isoforms.
Unlike PDE4D5, PDE4D9 does not show signs of 
androgen regulation despite being down-regulated in PCa 
and we could not find evidence for DNA methylation-
mediated regulation of PDE4D9 expression in PCa. Thus, 
its transcriptional regulation in PCa remains unclear at this 
point and solicits further study.
Taken together, the observed switch in isoform 
usage might imply that regulatory mechanisms of 
PDE4D-catalyzed cAMP degradation are subjected to 
AR signalling in PCa cells that, in turn, indicates that 
PDE4D7-specific protein domains are necessary to 
regulate cAMP signalling in an androgen-dependent 
manner, offering a potentially new drug target [15, 16, 18]. 
Moreover, with the transition to an androgen-independent 
state, expression of long PDE4D isoforms seems to fade, 
reaching its minimum in castration-resistant conditions 
and distant metastases, while expression of the super-short 
isoforms PDE4D1 and PDE4D2 appears to remain rather 
stable. Importantly, these super-short isoforms contain 
the catalytic domain of PDE4D but lack the UCR1/
UCR2 domains seen in long PDE4D isoforms, a module 
that confers regulation by various kinases and influences 
intracellular targeting [6, 18].
Oncotarget70679www.impactjournals.com/oncotarget
Hence, this effective loss of regulation of PDE4D 
activity can be expected to generate profound changes in 
compartmentalized cAMP signaling due to altered spatial 
localization and cross-talk governing cAMP degradation, 
and may thereby contribute to cancer aggressiveness 
similarly to mechanisms suggested for MAPKs [54] and 
AR in form of its splice variant AR-V7 [43].
PDE4D isoform composition appears to have merit 
in being used as a diagnostic signature following the 
expression of PDE4D7 and PDE4D5, as well as serving 
as a prognostic signature following the difference between 
the expression of long and short PDE4D isoforms. 
Evaluating both signatures, we found that they exhibited 
good performance in distinguishing PCa from normal 
tissue and progressive from non-progressive samples, 
respectively. Importantly, diagnostic performance was 
robust to differences in technology, data processing, as 
well as potential differences in composition and patient 
characteristics of the used cohorts, demonstrating a 
high cross-platform reproducibility of PDE4D isoforms 
as PCa biomarker and yielding results comparable to 
the established PCa-marker PCA3 in all tested cohorts. 
Hence, with further optimization to an appropriate test 
platform prior to clinical utilization, we could imagine 
that such signatures might provide a valuable addition to 
complement existing test procedures.
When applying our diagnostic signature to prostate 
biopsies, PDE4D isoform expression appeared to return 
to its ‘normal’ state with increasing distance from the 
tumour, whereas the tumour edge showed an intermediate 
signal. This observation could hint at a ‘field effect’ of 
the tumour on and/or crosstalk of the tumour cells with 
the surrounding microenvironment [55–58]. It would 
therefore be fascinating to further explore in the future 
whether such a ‘field effect’ indeed influences PDE4D 
isoform composition, effectively increasing the target area 
for biopsies, or whether our observations were caused by 
averaging signals from adjacent tumour and normal cells. 
If validated, an increased target area could boost accuracy 
of prostate biopsies, reducing the number of false negative 
tests. Furthermore, it would be highly interesting to see 
whether reversing the isoform composition to its normal 
state has an influence on prostate cell phenotype and 
behaviour.
While our study focused on PDE4D isoform 
expression in primary PCa samples, genomic alterations 
of the PDE4D locus such as microdeletions have been 
observed in other cancers [27]. Moreover, a recent study 
found that mutations in other members of the PDE family 
could be related to PCa by affecting intracellular cAMP 
and/or cGMP levels [59]. Considering the large number 
of PDE genes and isoforms as well as the tight regulation 
of cAMP signalling and its degradation, it is very well 
possible that PDEs such as PDE4D are key players in 
other conditions, as the broad panel of associated diseases 
underscores [10–14]. Therefore, it is worthwhile to extend 
the presented study and screen the expression profiles of 
all known PDEs in various tissues and conditions to define 
basal expression levels and reveal potential alterations and 
novel targets for drug interventions.
Taken together, our findings highlight the potential 
of PDE4D isoforms to be promising new biomarkers and 
potential therapeutic targets for localized and advanced 
prostate cancer.
MATERIALS AND METHODS
Analysis of PDE4D isoform expression in 
prostate tissues
Quantification of PDE4D isoforms in patient 
materials was performed by qRT-PCR as described in [16]. 
In addition, six independent Exon Array datasets were used 
in this study and raw CEL files were obtained via Gene 
Expression Omnibus (GEO) or personal communication. 
The datasets comprised GSE21034 [25], GSE29079 
[30], GSE46691 [60], GSE32875 [28] as well as patient 
samples from GSE41410 [61, 62] and samples published 
in [63]. These datasets are referred to as ‘Taylor’, ‘Brase’, 
‘Erho’, ‘Rajan’, ‘EMC’, and ‘Nijmegen’, respectively.
Of note, patients PCA0041, PCA0042 and PCA0119 
of the Taylor dataset were marked as ‘treated with salvage 
radical prostatectomy (RP)’, meaning they previously 
failed radiotherapy treatment and were subsequently 
treated with RP. Therefore, Exon Array expression data 
for PCA0119 were not used for survival analysis.
Raw data were processed and RMA normalized 
using the aroma.affymetrix R-package ([64], CDF used: 
HuEx-1_0-stv2,extendedR3,A20071112,EP.CDF, see 
http://www.aroma-project.org/). Expression of transcript 
isoforms was measured by using log2-transformed 
intensity values of isoform-specific probesets: PDE4D1/2 
(2858166); PDE4D3 (2858290, 2858291); PDE4D4 
(2858368, 2858369, 2858370); PDE4D5 (2858345, 
2858346, 2858347); PDE4D6 (2858155, 2858156); 
PDE4D7 (2858406, 2858407, 2858408); PDE4D8 
(2858257, 2858258); PDE4D9 (2858240, 2858241). These 
intensity values were normalized to a set of reference 
genes (HPRT1, PUM1, TBP, POLR2A, TUBA1B) by 
using the mean intensity of ‘core’ probesets of each gene’s 
transcript cluster (3991698, 2404254, 2937984, 3453732, 
3708704) to estimate gene expression and then using the 
average reference gene expression as normalization factor. 
This normalization factor was subtracted from the probeset 
intensity values, and normalized probeset expression was 
subsequently averaged per PDE4D isoform. In addition, 
expression of the PCa associated genes was normalized 
the same way as PDE4D, using ‘core’ and ‘extended’ 
probesets of transcript cluster 3175538 to measure PCA3 
as well as 3931765 for ERG and 2811145 for PART1.
Lastly, level 3 processed RNA-seq expression 
values for PRAD samples were obtained from TCGA 
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(https://tcga-data.nci.nih.gov/tcga/) via the TCGA-
Assembler R-package [65]. For each sample, the RSEM 
‘scaled estimate’ values were used and multiplied by 106 to 
convert the values to transcripts per million (TPM). Error 
bars in plots represent standard deviation unless stated 
otherwise.
Analysis of deletions of PDE4D and impact on 
isoform expression
Gene-level copy number alterations were obtained 
from TCGA via the TCGA-Assembler R-package [65] and 
a cut-off of ±log2(1.5/2) was used to call gains and losses 
of genetic material, respectively. A Wilcoxon-Mann-
Whitney test was used to identify significant changes in 
expression of PDE4D isoforms between samples with and 
without alterations.
Evaluation of AR and ERG expression / binding 
on PDE4D transcription
To determine the (TMPRSS2-)ERG status of 
patient samples in Exon Array cohorts, we used relative 
ERG expression values and applied Partitioning Around 
Medoids (PAM, R-package ‘cluster’, k = 2) to assign the 
patient samples to the ERG positive or negative group 
based on expression. Lastly, a Wilcoxon-Mann-Whitney-
test was used to detect statistically significant differences 
(p < 0.05) between the ERG positive and ERG negative 
samples. Likewise, differences between R1881 treated 
and untreated LNCaP cells [28] were tested using a 
Wilcoxon-Mann-Whitney-test. To investigate transcription 
factor binding, public ChIP-seq peaks for AR and ERG 
were obtained from GEO (GSE14092) and overlapped 
with PDE4D TSS ± 2 kb regions using bedtools [66] 
after conversion to hg19 coordinates using the liftOver 
executable (https://genome.ucsc.edu/cgi-bin/hgLiftOver). 
Distances of the nearest AR and ERG peaks to each 
PDE4D isoform TSS were calculated by ‘bedtools closest’ 
using the options ‘-k 5 and -d’. Data visualization was 
based on the ggBio R-package [67]. Enrichment of AR 
and ERG peaks in the PDE4D gene locus was investigated 
by counting the number of ChIP-seq peaks of each 
transcription factor within 21,209 RefSeq gene loci (hg19) 
as well as randomly sampled genomic regions of 1.5 Mb. 
Unique gene loci were defined by the minimum and 
maximum chromosomal coordinates of RefSeq NM and 
NR transcripts belonging to the same gene identifier after 
associating them to HGNC gene symbols using biomaRt 
[68] and excluding minor chromosomes and haplotypes. 
For each chromosome, random regions were sampled 
according to: number of regions = (chromosome size in 
Mb * 1000) and any regions overlapping the PDE4D gene 
locus were excluded. Counting was performed by bedtools 
[66] annotate using the option ‘-counts’ and empirical 
cumulative distribution functions for both transcription 
factors were created by using the ecdf() function of 
R-package stats. Hexbinplots were generated using the 
BoutrosLab.plotting.general R-package (http://labs.oicr.
on.ca/boutros-lab/software/bpg).
Investigation of PDE4D promoter methylation
Public methylation data were downloaded from 
GEO and TCGA data portal and comprised three 
different technologies. 1) Deduplicated and extended 
MeDIP-seq reads (200 nt) deposited under accession 
number GSE35342 [31] were downloaded from Gene 
Expression Omnibus (GEO) and processed via the 
MEDIPS R-package [69]. Using genomic bins of 100 nt 
for chromosome 5, reads were counted for every sample 
and differential methylation status of each bin was tested 
using the following MEDIPS settings as suggested 
by the authors upon request: ‘diff.method = “edgeR”, 
prob.method = “poisson”, MeDIP = F, CNV = F’. Bins 
covering the genomic region of PDE4D including 50 
kb flanks and with a Bonferroni-adjusted p-value below 
0.01 were selected and merged into larger regions of 
interest (ROIs) if they were directly adjacent. 2) Pre-
processed public bisulfite sequencing (BiS-seq) data 
available from GEO (GSE41701, [70]) were downloaded, 
and measured positions found in the genomic region of 
PDE4D including 50 kb flanks were extracted. For each 
position, the percentage of reads indicating methylation 
was calculated by #base calls C / (#base calls C + 
#base calls T) based on the number of reads covering a 
particular base. Next, the limma R-package [71, 72] was 
used to identify positions with significant differences in 
methylation between PCa vs. benign, as well as CRPC 
vs. PCa. Positions with FDR < 0.05 were selected and 
merged into larger regions if they were within 100 nts of 
each other. 3) TCGA level 3 data for Illumina Infinium 
HumanMethylation450 BeadChips were downloaded from 
TCGA data portal and only patients with available clinical 
information were used for further analysis. Pre-calculated 
beta values for chromosome 5 were imported into Minfi 
[73] and annotated using ‘ilmn12.hg19’. Analysis of 
differential methylation was performed via bumphunter 
using 100 permutations and ‘cutoff=0.15’. Lastly, any 
significant probes located within the genomic region 
of PDE4D including 50 kb flanks were extracted and 
methylation profiles were correlated to RNA expression 
via Spearman’s correlation coefficient. Visualisation of 
methylated regions was performed using ggBio [67].
Analysis of signature performance, survival and 
independent predictor variable
We created a diagnostic signature based on 
PDE4D7 expression relative to PDE4D5 expression 
(PDE4D7-PDE4D5) as well as a prognostic signature 
for the Exon Array cohorts based on PDE4D1/2 relative 
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to PDE4D5, PDE4D7 and PDE4D9 ((PDE4D1/2) - 
(PDE4D5+PDE4D7+PDE4D9)). Subsequently, the 
R-packages ‘ROC’ and ‘survival’ were used to carry out 
ROC analyses and perform a Cox regression as well as 
Kaplan-Meier analysis based on available survival data of 
the EMC dataset [61, 62].
Quantification of diagnostic PDE4D signature in 
prostate biopsies
Several biopsy punches (approximately 1 x 2 mm) 
were taken in a representative tumour area after surgical 
prostate resections in eighteen different men with prostate 
cancer. Experimental protocols were approved by the 
Erasmus MC Medical Ethics Committee following the 
Medical Research Involving Human Subjects Act. For 
each patient, these punches were performed within the 
tumour, at the edge of the tumour area, at 5 and at 10 
mm distance to the tumour region. RNA was extracted 
and qRT-PCRs (quantitative real-time PCR) for PDE4D5 
and PDE4D7 were performed as described in [16], using 
ACTB, HPRT1, TUBA1B, POLR2A, PUM1 and TBP 
as reference genes. The expression of PDE4D5 and 
PDE4D7 in each biopsy tissue was normalized as follows: 
mean(Ct(reference genes)) – Ct(PDE4DX). For each of 
the eighteen different patients, the normalized expression 
of PDE4D transcripts within the tumour was set to 1 and 
expression values for biopsies taken at various distances 
from the tumour were calculated relative to the expression 
in the tumour. Lastly, average relative expression and 
standard error of the mean of PDE4D transcript expression 
were plotted for each of the respective biopsy locations.
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